What Makes Sodium-Glucose Co-Transporter-2 Inhibitors Stand out in Heart Failure?

被引：0
|
作者：
Muhammad Shahzeb Khan
Muthiah Vaduganathan
机构：
[1] Cook County Health and Hospital System,Department of Medicine
[2] Brigham and Women’s Hospital Heart & Vascular Center and Harvard Medical School,Heart and Vascular Center
来源：
Current Diabetes Reports | 2020年 / 20卷
关键词：
Antihyperglycemic therapies; Diabetes mellitus; Heart failure; SGLT-2 inhibitors;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [31] Effect of Sodium-Glucose Co-transporter-2 Inhibitors on Ventricular Repolarization Markers in Heart Failure with Reduced Ejection Fraction
    Emre Yılmaz
    Ertan Aydın
    Sencer Çamcı
    Devrim Kurt
    Ercan Aydın
    [J]. Cardiovascular Drugs and Therapy, 2024, 38 : 327 - 333
  • [32] RENAL EFFECTS OF SODIUM-GLUCOSE CO-TRANSPORTER-2 INHIBITORS IN PATIENTS WITH HEART FAILURE WITH REDUCED OR PRESERVED EJECTION FRACTION
    Patoulias, Dimitrios
    Katsimardou, Alexandra
    Boulmpou, Aristi
    Siskos, Fotios
    Imprialos, Konstantinos
    Stavropoulos, Konstantinos
    Zografou, Ioanna
    Papadopoulos, Christodoulos
    Doumas, Michael
    [J]. JOURNAL OF HYPERTENSION, 2022, 40 (SUPPL) : E70 - E70
  • [33] Sodium-glucose co-transporter-2 inhibitors in patients treated with immune checkpoint inhibitors
    Perelman, Moran Gvili
    Brzezinski, Rafael Y.
    Waissengrin, Barliz
    Leshem, Yasmin
    Bainhoren, Or
    Rubinstein, Tammi Arbel
    Perelman, Maxim
    Rozenbaum, Zach
    Havakuk, Ofer
    Topilsky, Yan
    Banai, Shmuel
    Wolf, Ido
    Laufer-Perl, Michal
    [J]. CARDIO-ONCOLOGY, 2024, 10 (01)
  • [34] Sodium-glucose co-transporter-2 inhibitors in patients treated with immune checkpoint inhibitors
    Moran Gvili Perelman
    Rafael Y. Brzezinski
    Barliz Waissengrin
    Yasmin Leshem
    Or Bainhoren
    Tammi Arbel Rubinstein
    Maxim Perelman
    Zach Rozenbaum
    Ofer Havakuk
    Yan Topilsky
    Shmuel Banai
    Ido Wolf
    Michal Laufer-Perl
    [J]. Cardio-Oncology, 10
  • [35] Myeloproliferative Neoplasms and Sodium-Glucose Co-Transporter-2 Inhibitors: A Case Series
    Patir, Pusem
    Cerci, Kubra
    Kurtoglu, Erdal
    [J]. TURKISH JOURNAL OF HEMATOLOGY, 2024, 41 (02) : 130 - 132
  • [36] An update on sodium-glucose co-transporter-2 inhibitors for the treatment of diabetes mellitus
    Hsia, Daniel S.
    Grove, Owen
    Cefalu, William T.
    [J]. CURRENT OPINION IN ENDOCRINOLOGY DIABETES AND OBESITY, 2017, 24 (01) : 73 - 79
  • [37] The effect of sodium-glucose co-transporter-2 inhibitors on markers of subclinical atherosclerosis
    Stachteas, Panagiotis
    Karakasis, Paschalis
    Patoulias, Dimitrios
    Clemenza, Francesco
    Fragakis, Nikolaos
    Rizzo, Manfredi
    [J]. ANNALS OF MEDICINE, 2023, 55 (02)
  • [38] Effects of Sodium-Glucose Co-Transporter-2 Inhibitors on Markers of Vascular Damage
    Kourtidou, Christodoula
    Rafailidis, Vasileios
    Varouktsi, Garyfallia
    Kanakis, Efthimios
    Liakopoulos, Vassilios
    Vyzantiadis, Timoleon-Achilleas
    Savopoulos, Christos
    Marinaki, Smaragdi
    Stangou, Maria
    Tziomalos, Konstantinos
    [J]. JOURNAL OF PERSONALIZED MEDICINE, 2023, 13 (03):
  • [39] Updated Meta-Analysis Evaluating the Beneficial Effects of Sodium-Glucose Co-Transporter-2 Inhibitors in Patients With Heart Failure
    Patoulias, Dimitrios
    Papadopoulos, Christodoulos
    Kassimis, George
    Boulmpou, Aristi
    Karagiannis, Asterios
    Doumas, Michael
    [J]. AMERICAN JOURNAL OF CARDIOLOGY, 2021, 161 : 118 - 120
  • [40] Preventing and Treating Heart Failure with Sodium-Glucose Co-Transporter 2 Inhibitors
    Vaduganathan, Muthiah
    Januzzi, James L., Jr.
    [J]. AMERICAN JOURNAL OF CARDIOLOGY, 2019, 124 : S20 - S27
12345